Patent Working Requirement

A patent working requirement is a condition imposed by some national patent laws that requires the patent holder to commercially exploit — 'work' — the patented invention in that country within a specified period after grant, or face consequences such as compulsory licensing or patent revocation. The concept is rooted in the idea that patents are a social bargain: the public grants the inventor a monopoly in exchange for public disclosure AND commercial exploitation of the invention in the granting country. A patent that is never worked in the country — one that blocks others from practicing the invention locally but produces no local goods, manufacturing jobs, or technology transfer — is seen by some countries as providing no reciprocal benefit. Working periods are typically 3 years from grant or 4 years from the filing date, whichever is later. The consequence of non-working is generally not automatic revocation but rather the ability of a third party to apply for a compulsory license — the government forces the patent holder to license the technology to someone who will work it locally. The definition of 'working' is critical and varies by country: some countries accept importation of patented products as sufficient (because the domestic market is served); others, particularly Brazil, require local manufacturing. The United States, European Union, and Japan do not impose patent working requirements. Brazil, India, Argentina, and many developing countries do. The WTO debate over whether TRIPS Article 27.1 prohibits working requirements remains unresolved.

It depends on the country, and this is one of the most practically important distinctions for international patent filers. Three distinct approaches: (1) Importation DOES satisfy working (broader interpretation): China, Mexico (with conditions), and many countries interpret 'working' broadly enough to include supplying the domestic market through importation. If the patent holder is selling patented products in that country — even if manufactured abroad — the working requirement may be satisfied. (2) Importation does NOT satisfy working (strict local manufacture required): Brazil's Industrial Property Law explicitly requires 'manufacture' in Brazil. Importation of a pharmaceutical product manufactured in the United States or Europe into Brazil does not satisfy the working requirement, even if Brazilian patients can buy the product. This is the most onerous interpretation and has led to compulsory licensing threats in the pharmaceutical sector. (3) Importation may satisfy if 'to the fullest extent reasonably practicable': India's standard — working is evaluated based on whether the patent holder has commercially exploited the invention to the extent commercially feasible, and importation can satisfy if local manufacturing is not reasonably practicable given cost, technology, or market constraints. This creates a defense for multinational patentees that can demonstrate manufacturing in Brazil or India is not commercially viable. Practical guidance: multinational companies should assess working requirements country-by-country at portfolio level. For patents in Brazil, India, Mexico, and Argentina in particular, working compliance or a working defense should be part of the standard post-grant management review. Compulsory license risk is highest in the pharmaceutical sector, where local working requirements are most strictly enforced.

In Brazil, failure to locally manufacture a patented invention within 3 years of patent grant exposes the patent to a compulsory license application by any interested third party. The process: (1) The third party (typically a domestic manufacturer who wants to produce the patented product) applies to INPI (the Brazilian National Institute of Industrial Property) for a compulsory license, demonstrating that the patent is not being locally worked. (2) INPI notifies the patent holder and gives them an opportunity to demonstrate working or to justify non-working. (3) If INPI determines the patent is not worked and the patent holder's justification is insufficient, it may grant the compulsory license on terms it determines — including royalty rate and duration. (4) The patent holder retains patent ownership but is compelled to allow the licensed manufacturer to produce the patented product in Brazil. In practice, Brazil's compulsory licensing mechanism has been most actively used in the pharmaceutical sector and has been a negotiating tool even when formal compulsory licenses are not ultimately granted — the threat of a compulsory license has led to voluntary price reductions or licensing agreements. The Brazilian government (as distinct from third-party applicants) can also invoke government use compulsory licensing under Art. 71 of the Industrial Property Law for national emergency situations (as it did for HIV antiretrovirals in 2007, issuing a compulsory license for efavirenz). U.S. pharmaceutical and technology companies with significant Brazilian patent portfolios should track working compliance and consider whether engaging a Brazilian manufacturer under a license agreement would satisfy the working requirement while generating local revenue.

This is one of the most contested interpretive questions in international patent law, and it has not been definitively resolved. TRIPS Agreement Article 27.1 states that patent rights 'shall be enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced.' The United States, European Union, and most developed nations argue that this language prohibits working requirements that require local manufacture, because such requirements discriminate against patent holders based on whether their products are imported or locally produced (i.e., a patent holder who manufactures locally is not subject to compulsory licensing, but one who imports is). Brazil, India, and other developing nations counter that: (1) TRIPS Article 27.1 is not absolute — Articles 30 (limited exceptions) and 31 (compulsory licensing) expressly permit restrictions on patent rights for public interest reasons, including working requirements; (2) the Doha Declaration on TRIPS and Public Health (2001) reaffirmed members' rights to use TRIPS flexibilities to protect public health and promote access to medicines — working requirements are among those flexibilities; (3) the non-discrimination provision in Art. 27.1 governs what subject matter is patentable, not what conditions may be imposed after grant. Neither Brazil nor India has faced a successful WTO dispute settlement challenge specifically targeting working requirements. The legal question remains open, and both countries maintain active working requirement programs. The United States addresses the issue through bilateral trade agreements and the Special 301 Report process (designating countries with IP enforcement concerns), but has not pursued WTO dispute settlement.

A practical approach for U.S. companies with international patent portfolios: (1) Identify countries in the portfolio with active working requirements — Brazil, India, Argentina, and Mexico are the highest priority. Other countries with working requirements (Turkey, South Africa, Philippines) warrant periodic review but are lower urgency for most portfolios. (2) For each high-priority country, assess whether the patent is being commercially exploited in that country — through local manufacture, licensing to a local manufacturer, or importation (where importation satisfies). Keep contemporaneous records of sales, licensing activity, and the scope of commercial exploitation. (3) Where local exploitation is minimal or absent, evaluate three responses: (a) grant a license to a local manufacturer or distributor who will work the invention — this satisfies the working requirement and generates royalty revenue; (b) document why local manufacturing is not commercially reasonably practicable (no local manufacturing capacity, insufficient market scale) — this is the primary defense in India and may be relevant in other jurisdictions; (c) allow the patent to lapse in countries where the working requirement creates risk and the commercial value doesn't justify the compliance effort. (4) In Brazil specifically, working means local manufacturing — importation is not a defense. If a Brazilian patent covers a product you sell in Brazil but manufacture elsewhere, you face ongoing compulsory licensing risk. Options: license a Brazilian manufacturer, establish local manufacturing (if commercially viable), or accept the risk with monitoring. (5) India requires annual Form 27 filings on patent working status — non-compliance is a separate violation from non-working. Ensure in-house counsel or a local Indian patent agent is filing Form 27 for each granted Indian patent. (6) Integrate working compliance into standard annual patent portfolio reviews — not just renewability (maintenance fees paid, continuation opportunities), but also working compliance status in each key jurisdiction.